-+ 0.00%
-+ 0.00%
-+ 0.00%

Biohaven Presents Clinical Data From Ongoing Phase 1 Study Of BHV-1530, Potential FGFR3-Directed ADC With Topoisomerase I Payload, At ENA 2026

Benzinga·11/19/2026 12:35:53
Listen to the news

Phase 1 data presented in an oral plenary session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain, showed deep and durable responses in patients with FGFR3-altered urothelial cancer (UC) and head and neck squamous cell carcinoma (HNSCC). As of the data cutoff in the ongoing study, 6 of 10 evaluable patients with FGFR3 activating alterations treated at doses of ≥3.3 mg/kg had responded, including 3 of 5 with UC and 3 of 3 with HPV-positive HNSCC.

  • Responders to BHV-1530 in UC included patients who failed prior enfortumab vedotin plus pembrolizumab (EV+P) and oral FGFR tyrosine kinase inhibitors. All responders remained on treatment at data cutoff, some beyond 6 months.
     
  • BHV-1530 was well tolerated with no FGFR class toxicities: no DLTs, treatment-related SAEs or deaths, and no ILD; no hyperphosphatemia, nail dystrophy or central serous retinopathy.
     
  • Biohaven completed FDA Type C meeting in 4Q 2026 and plans to initiate a pivotal study evaluating BHV-1530 in FGFR3-altered tumors, starting with UC, expected to begin as early as 1H 2027 to support potential accelerated approval.

BARCELONA, Spain and NEW HAVEN, Conn., Nov. 19, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced clinical data from the ongoing Phase 1 study of BHV-1530, its first in class potential FGFR3-directed antibody-drug conjugate (ADC) with a novel topoisomerase I (TopoIx) payload. The data were presented today by Gerald S. Falchook, M.D., Director of Sarah Cannon Research Institute at HCA HealthONE, in an oral presentation during Plenary Session 3 at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain. As of the October 19, 2026 data cutoff, 30 patients had received BHV-1530 monotherapy every three weeks (Q3W) at doses from 1.0 to 12.0 mg/kg, and dose escalation is ongoing. Patients had received a median of two prior lines of therapy for advanced disease, and all patients with UC had progressed on EV+P.

Among 10 efficacy-evaluable patients with activating FGFR3 alterations, treated with BHV-1530 at doses of 3.3 mg/kg or higher, 9/10 had a tumor reduction and 6 achieved a partial response (PR; confirmed or unconfirmed, by investigator assessment per RECIST v1.1; Figure 1). Responses were observed in tumors with FGFR3 mutations and fusions, including in 3 of 5 patients with UC and all 3 patients with HPV-positive HNSCC. All responders remained on treatment as of the data cutoff, some for more than 6 months.